OCS OCULIS HOLDING AG

Oculis to Participate at Upcoming April Investor Conferences

Oculis to Participate at Upcoming April Investor Conferences

ZUG, Switzerland and BOSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis’s management will be attending and presenting at the following upcoming investor conferences:

Needham Annual Virtual Healthcare Conference

Format: Corporate presentation

Presenter: Riad Sherif, MD, Chief Executive Officer

Presentation date and time: April 11, 2024 at 8:00 am EDT

Location: Virtual

Webcast:

Van Lanschot Kempen Life Sciences Conference

Date: April 16-17, 2024

Location: Amsterdam, the Netherlands

The Company will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representative to request meetings.

About Oculis

Oculis (Nasdaq: OCS) is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis’s highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Oculis’s goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.

For more information, please visit:

Oculis Contacts

Ms. Sylvia Cheung, CFO

Investor & Media Relations

LifeSci Advisors

Corey Davis, Ph.D.



1-212-915-2577



EN
04/04/2024

Underlying

OCSOCULIS HOLDING AG

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OCULIS HOLDING AG

 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmol...

Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtual Conference ZUG, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic conditions with significant unmet medical needs, today announced that Oculis’ management will be participating in the H.C Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025. Sylvia Cheung, Oculis’ Chief Financial Officer, will be presenting a corporate update which will...

August 12, 2025 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmo...

Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference ZUG, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic conditions with significant unmet medical needs, today announced that Oculis’ management will be participating in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025. Sylvia Cheung, Oculis’ Chief Financial Officer, will be presenting a corporate update whic...

August 12, 2025 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Upsized Loan Facility to Access up to CHF 100 million

Oculis Upsized Loan Facility to Access up to CHF 100 million ZUG, Switzerland, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that it has amended its loan facility (the “Amended Loan Agreement”) with funds and accounts managed by BlackRock (the “Lender”). The Amended Loan Agreement replaces the prior loan agreement between Oculis and the Lender dated May 29, 2024, an...

August 1, 2025 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis hækkar lánsheimild sína og fær aðgang að allt að 100 milljónum ...

Oculis hækkar lánsheimild sína og fær aðgang að allt að 100 milljónum CHF ZUG, Sviss, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) („Oculis“ eða „félagið“), alþjóðlegt líftæknifyrirtæki með áherslu á nýsköpun við meðferð á augn- og augntaugasjúkdómum í því skyni að mæta verulegum óuppfylltum læknisfræðilegum þörfum, greinir frá því í dag að breytingar hafa verið gerðar á lánssamningi félagsins („breytti lánssamningurinn“) við sjóði í stýringu hjá BlackRock („lánveitandi“). Breytti lánasamningurinn kemur í stað fyrri lánssamnings, sem gerður var þann 29. m...

August 1, 2025 1 EN
 PRESS RELEASE
Free
OCS OCULIS HOLDING ...

Oculis Upsized Loan Facility to Access up to CHF 100 million

Oculis Upsized Loan Facility to Access up to CHF 100 million ZUG, Switzerland, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that it has amended its loan facility (the “Amended Loan Agreement”) with funds and accounts managed by BlackRock (the “Lender”). The Amended Loan Agreement replaces the prior loan agreement between Oculis and the Lender dated May 29, 2024, an...

August 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch